Related Experiment Video
Updated: May 4, 2026
A Modular Workflow for Quantitative, Structural and Functional Analysis of Leptospira Biofilms
Published on: December 19, 2025
[Use of infusion solution remaxol in the combination treatment of patients with leptospirosis]
Aim:
To evaluate the efficiency of using remaxol in the combination treatment of patients with leptospirosis.
Subjects And Methods:
Thirty patients (29 men and 1 woman) with leptospirosis were treated with remaxol. The icteric and anicteric forms of the disease were diagnosed in 28 and 2 patients, respectively. Moderate, severe, and very severe leptospirosis were observed in 3, 24, and 3 cases, respectively. Remaxol was injected intravenously as a ready-to-use infusion solution 400 ml/day; the treatment duration was 3 to 9 days at the height of the disease.
Results:
Clinical improvement and normalization of laboratory parameters were achieved in the course of the disease. There were no deaths. During early convalescence at 4-5 weeks of the disease, the patients taking remaxol at the height of the disease were substantially more rarely recorded to have general weakness, fever, anorexia, myalgia, leukocytosis, increased erythrocyte sedimentation rate, and hyperbilirubinemia than those untreated with this drug.
Conclusion:
The performed study established the clinical efficacy of remaxol when used in the combination treatment of patients with leptospirosis.
Insights
Remaxol effectively treated leptospirosis patients, leading to clinical improvement and normalization of lab results without any deaths. Patients receiving remaxol experienced fewer lingering symptoms during convalescence.
Area of Science:
- Infectious Diseases
- Hepatology
- Pharmacology
Background:
- Leptospirosis is a serious bacterial infection with significant morbidity.
- Effective treatment strategies for leptospirosis are crucial for patient outcomes.
- Combination therapies are often employed to manage severe infectious diseases.
Purpose of the Study:
- To assess the efficacy of remaxol as part of a combination treatment for leptospirosis.
- To evaluate the impact of remaxol on clinical and laboratory parameters in leptospirosis patients.
Main Methods:
- A study involving 30 patients diagnosed with leptospirosis (28 icteric, 2 anicteric).
- Patients received intravenous remaxol (400 ml/day) for 3-9 days during the acute phase.
- The study included patients with moderate, severe, and very severe forms of the disease.
Main Results:
- All patients treated with remaxol showed clinical improvement and normalized laboratory values.
- No mortality was observed in the remaxol-treated group.
- Patients receiving remaxol experienced reduced incidence of weakness, fever, anorexia, myalgia, leukocytosis, elevated ESR, and hyperbilirubinemia during early convalescence compared to untreated patients.
Conclusions:
- Remaxol demonstrated clinical efficacy when incorporated into the combination treatment of leptospirosis.
- The use of remaxol in leptospirosis management appears to improve recovery and reduce persistent symptoms.
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:26Pharmaceutical Poisoning: Treatment Strategies
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions